등록정정(특)
1. The plaintiff's claim is dismissed.
2. The costs of litigation shall be borne by the Plaintiff, including those incurred by participation.
1. Basic facts
A. The title of the patented invention of this case (Evidence A 1 and 2) 1: C2); the international filing date / the priority claim date / the registration date / the registration number : Claims D/ 7 March 7, 2005: see the following (d) claims 4). The main background technology and its problems are new pharmaceutical products and independent medicine, or related to the use and the manufacturing method thereof to treat excessive proliferation disorder like cancer by using new pharmaceutical products and separate medicines.
It is clearly indicated that the DNA biphenyl of the chemical formula (I) below (001) and its limit are a strong suppression of raf, VEGFR-2, p38 and PDGFR key.
(Identification Number(002). Despite the development described in the current industry in relation to key control, the demand for improved medicine for cancer treatment remains.
In particular, there is a demand for improved light-saving products that can increase patient's net response as easily as possible.
(Identification Number (005). The purpose of the invention of this case for the purpose of the patent invention of this case is to provide pharmaceutical products, including chemical (I) compounds to be applied not more than three times a day in order to achieve the effective blood concentration of chemical (I) compounds.
In the case of refining or capsuling products as pharmaceutical products of light-gu, the above-mentioned products shall not be so big that they can be able to be able to be able to be able to be able to be able to be able to be able to be d
(Identification Number(006). The invention of the principle of organizing the task or resolving the task adopted for technical tasks is about the pharmaceutical products including chemical(I) compounds of high concentration and subsidiary agents permitted for not less than one kind of restriction.
(Identification Number(007). Egypt (007). The bio-use rate of chemical compounds (I) shall be equal to that of chemical compounds and the effective blood concentration shall be achieved.
In addition, pharmaceutical products under this invention will provide a good safety of chemical (I) compounds.
(1) the identification number;